Crystal Anglen Email & Phone Number

San Francisco, Ca, Us

South San Francisco, California, Us

Excellence in Medical Affairs Consulting to advance patient careSpecializing in Strategy Development, Medical Education, Scientific Communications, Publication Planning, Elevating the Patient Voice, Thought Leader Engagement, Scientific Messaging, Competitive Intelligence, Congress PlanningPatient-centric. Strategic. Principled.

Hellerup, Capital Region Of Denmark, Dk

• Lead development and implementation of Medical Communications & Education activities across the Ascendis Pharma portfolio of endocrinology molecules• Lead Publication Planning Teams for Growth Hormone Deficiency, Hypoparathyroidism, and Achondroplasia therapeutic areas, maintaining messages, timelines, and abstract and manuscript deliverables• Perform literature review and gap analysis to develop strategic, long-term Publication Plans• Oversee Medical Education strategy and programming for growth disorders, including CME, from needs assessment to program implementation• Drive strategy and scientific content development for scientific meetings, including execution of congress deliverables, disease state education programs, Symposia, and advisory boards• Establish and lead Grants Review Committee and manage educational grants portfolio• Serve as Medical Affairs delegate in cross-functional teams including GH Launch Team, Promotional Review Committee, Market Access, Conference Planning, Clinical Subteams, Core Teams, and Executive Forums• Oversee budgeting for Medical Affairs functions• Maintain expert understanding of portfolio, product knowledge and labeling, associated disease states, relevant literature, treatment guidelines, disease landscape, and marketing strategies and tactics• Perform critical analysis of scientific data and interpret significance to communicate implications cross-functionally

Hellerup, Capital Region Of Denmark, Dk

Dublin, 2, Ie

● Following a patient-centric approach, integrated the patient voice into corporate decision-making at every step of drug development to improve product and health outcomes for individuals affected by rare diseases such as AL amyloidosis and ATTR amyloidosis● Created and implemented Global Patient Engagement Plan, which identified strategic areas of company focus and opportunities for partnership with key international advocacy groups, medical and patient communities, and policymakers● Designed and implemented advisory boards and focus groups in order to better understand needs and preferences of physicians, patients, and caregivers. Lead company’s first-ever Patient Advisory Board to gather insights on design of phase 1 protocol for ATTR amyloidosis● Championed patient voice to internal Product Teams and Leadership Team. Collaborated with Clinical, Regulatory, Manufacturing, Legal, and Communications functions to ensure the needs of key stakeholders are understood and considered in development programming● Reinvented clinical research models by recognizing patients as credible experts, advised clinical teams on patient perspective, and worked to develop new, relevant endpoints for clinical trials. Developed patient recruitment strategies and trial-specific patient materials that support clinical trial recruitment efforts● Created educational programs for both medical and patient communities through outcomes-oriented approach with measurable results. Recognized educational gaps and strategically work with communities to fill ● Managed Medical Affairs-Advocacy program budgets including congresses, advisory boards, educational grants, and charitable contributions

Leiden, Zuid-Holland, Nl

(Director, Medical and Patient Community Engagement 2015-2016; Lead, Scientific Affairs 2014 – 2015)● Pioneered a patient-centric corporate approach by highlighting the needs of patients and elevating insights of communities affected by rare genetic diseases such as Cystic Fibrosis (CF) and inherited retinal disease● Built and implemented global patient advocacy strategies by engaging international advocacy groups, patient and medical communities, and with internal stakeholders● Championed the patient voice internally through Clinical, Non-Clinical Research, Regulatory, Manufacturing, Legal, Communications, and Product Teams to ensure the needs of the patient community were understood and considered in business decision-making● Organized and led Advisory Boards involving patient advocates as well as leaders in the medical community and advised directly with Clinical Operations to design clinical trials. Pioneered a global Patient Advocacy Advisory Board to understand needs of CF patients around the world● Disseminated patient insights to inform strategic decisions of Program and Management Teams● Within the patient community, acted as a direct and reliable point of contact, personally responding to needs and requests● Directed all Scientific Affairs activities, including establishing operations for processes, policies, and strategies for molecules in both preclinical and early stages of development● Participated in FDA taskforce to consult on scientific and medical strategy in filing of IND and preparations for Type C meeting● Led scientific exchange with lead toxicology KOLs in development of white paper for IND filing● Chaired cross-functional Publication Team and developed strategic publication plans across therapeutic areas● Monitored competitive intelligence to continually define molecule’s unique space within the therapeutic landscape

Foster City, Ca, Us

(Associate Manager, 2008-2010; Manager 2010-2012; Senior Manager, 2012-2014)● Developed research strategies and priorities for Investigator-Initiated Research program in cardiopulmonary franchise including Pulmonary Arterial Hypertension (PAH) and CF. Executed strategies by chairing cross-functional Investigator-Initiated trial sub-teams, critically evaluating proposals, monitoring study status and operations, cultivating and maintaining relationships with external investigators, and managing resultant publications● Provided strategic medical and scientific input to design of phase IV trials and collaborative research initiatives● Chaired high-level Publication Strategy teams, utilizing literature searches and gap analysis to guide planning● Assessed relevant disease-state and competitive information to inform Plan of Action direction through global conference engagement ● Designed and developed scientific materials for corporate Advisory Boards for both Medical Affairs and Commercial Teams● Led Medical Science Liaison new hire and topical ad hoc training. Collaborated with MSLs to produce needed proactive and reactive presentations. Served as Medical lead in new hire Sales Training and National Commercial Education initiative designed to engage the Sales force and improve disease state knowledge● Developed educational programs to strengthen relationships with community advocacy organizations and cooperative research groups to benefit patients with PAH and CF● Provided key medical input into Commercial planning activities to ensure alignment of medical strategy with Brand Plan

Us

● Provided strategic scientific and medical expertise for product indications and life-cycle management across both pipeline (autoimmune) and in-line (oncology/hematology) products● Conducted review of all educational grants and Investigator-Initiated Studies for scientific merit and consistency with corporate and clinical strategies● Identified key clinical opportunities for product growth and provided an objective strategic viewpoint based on in-depth analysis of commercial and clinical competitive information● Designed and executed marketing conditioning strategies such as publication planning, Advisory Boards, CME materials, educational slides, and internal and external training● Developed and cultivated relationships with international, national, and regional key opinion leaders● Applied optimal regulatory compliance framework to all medical education initiatives

La Jolla, California, Us

Phd, Neuroscience, Immunology

Ba, Psychology (Neuroscience)